Ätiologie und Management der Gicht [The etiology and management of gout].

Détails

ID Serval
serval:BIB_B7E8B8A885B8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Ätiologie und Management der Gicht [The etiology and management of gout].
Périodique
Zeitschrift Für Rheumatologie
Auteur(s)
Pazár Maldonado B., So A.
ISSN
1435-1250 (Electronic)
ISSN-L
0340-1855
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
71
Numéro
2
Pages
127-36; quiz 137
Langue
allemand
Notes
Publication types: English Abstract ; Journal Article ; Review
Résumé
Gout is an inflammatory arthritis caused by monosodium urate (MSU) crystal deposits in and around the joint. The formation of urinary calculi can also occur in gout, but are less common than arthritis. Gout usually presents with recurrent episodes of joint inflammation, which over time lead to tophus formation and joint destruction. In the last decade, significant advances have been made regarding not only the epidemiology and genetics of gout and hyperuricemia but also the mechanisms of inflammation and treatment of gout. In addition, knowledge concerning the key role of interleukin 1 (IL-1) has provided new therapeutic perspectives. However, the current management of gout is often suboptimal, with many Patienten either not receiving adequate treatment or being unable to tolerate existing treatments. New therapeutic agents provide interesting new options for Patienten with difficult-to-treat gouty arthritis.The English full-text version of this is available at SpringerLink (under "Supplemental").
Mots-clé
Arthritis, Gouty/diagnosis, Arthritis, Gouty/drug therapy, Cross-Sectional Studies, Dose-Response Relationship, Drug, Drug Therapy, Combination, Gout Suppressants/adverse effects, Gout Suppressants/therapeutic use, Humans, Interleukin-1beta/antagonists & inhibitors, Interleukin-1beta/physiology, Risk Factors, Treatment Outcome
Pubmed
Web of science
Création de la notice
01/04/2012 14:13
Dernière modification de la notice
20/08/2019 15:26
Données d'usage